Patients with age <50 years, black race, poorly and/or undifferentiated disease, infiltrating ductal carcinoma (IDC), hormone receptor negative disease, and HER2 positive disease were more likely to be treated with chemotherapy (all P < .001). This evidence concerns the gene NR4A1 and invasive ductal breast carcinoma.